Disruptive Technologies Transforming Upstream Process Intensification for All Modalities

Accelerating the Future of Biopharmaceuticals with Cutting-Edge Perfusion Technology

How XCell® ATF is reshaping the landscape of biologics production across a variety of cell types and applications.

Dive into the heart of bioprocessing innovation with key insights:

• Perfusion technology dramatically increases cell densities to over 200 million cells/mL with CHO cells.
• Achieves a 3-5x improvement in viral yield in vaccine manufacturing using N and N-1 perfusion strategies.
• The XCell® ATF System is globally recognized, with over 500 installations enhancing productivity in biomanufacturing.
• Supports a wide range of molecules and cell types, proving its versatility and efficiency across the board.
• Offers significant cost savings and reduced environmental footprint, contributing to more sustainable manufacturing practices.

Unlock the full potential of your biologics pipeline with our in-depth analysis on XCell® ATF technology. Download now.

White Paper from